HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids.

AbstractBACKGROUND AND AIMS:
For HIV-positive individuals who use illicit opioids, engagement in methadone maintenance therapy (MMT) can contribute to improved HIV treatment outcomes. However, to our knowledge, the role of methadone dosing in adherence to antiretroviral therapy (ART) has not yet been investigated. We sought to examine the relationship between methadone dose and ART adherence among a cohort of people who use illicit opioids.
DESIGN AND SETTING:
We used data from the AIDS Care Cohort to Evaluate Access to Survival Services (ACCESS) study, an ongoing prospective observational cohort of HIV-positive people who use illicit drugs in Vancouver, Canada, linked confidentially to comprehensive HIV treatment data in a setting of universal no-cost medical care, including medications. We evaluated the longitudinal relationship between methadone dose and the likelihood of ≥ 95% adherence to ART among ART-exposed participants during periods of engagement in MMT.
PARTICIPANTS:
Two hundred and ninety-seven ART-exposed individuals on MMT were recruited between December 2005 and May 2013 and followed for a median of 42.1 months.
MEASUREMENTS:
We measured methadone dose at ≥ 100 versus < 100 mg/day and the likelihood of ≥ 95% adherence to ART.
FINDINGS:
In adjusted generalized estimating equation (GEE) analyses, MMT dose ≥ 100 mg/day was associated independently with optimal adherence to ART [adjusted odds ratio (AOR) = 1.38; 95% confidence interval (CI) = 1.08-1.77). In a subanalysis, we observed a dose-response relationship between increasing MMT dose and ART adherence (AOR = 1.06 per 20 mg/day increase, 95% CI = 1.00-1.12).
CONCLUSION:
Among HIV-positive individuals in methadone maintenance therapy, those receiving higher doses of methadone (≥ 100 mg/day) are more likely to achieve ≥ 95% adherence to antiretroviral therapy than those receiving lower doses.
AuthorsLeslie Lappalainen, Seonaid Nolan, Sabina Dobrer, Cathy Puscas, Julio Montaner, Keith Ahamad, Huiru Dong, Thomas Kerr, Evan Wood, M-J Milloy
JournalAddiction (Abingdon, England) (Addiction) Vol. 110 Issue 8 Pg. 1330-9 (Aug 2015) ISSN: 1360-0443 [Electronic] England
PMID25940906 (Publication Type: Journal Article, Observational Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright© 2015 Society for the Study of Addiction.
Chemical References
  • Analgesics, Opioid
  • Anti-HIV Agents
  • Illicit Drugs
  • Methadone
Topics
  • Adult
  • Analgesics, Opioid (administration & dosage)
  • Anti-HIV Agents (therapeutic use)
  • British Columbia
  • Dose-Response Relationship, Drug
  • Female
  • HIV Seropositivity (complications, drug therapy)
  • Humans
  • Illicit Drugs
  • Male
  • Medication Adherence
  • Methadone (administration & dosage)
  • Middle Aged
  • Opioid-Related Disorders (complications, rehabilitation)
  • Prospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: